Vical Inc. (NASDAQ:VICL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “

Separately, HC Wainwright reiterated a “buy” rating on shares of Vical in a research note on Tuesday, July 19th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Vical (NASDAQ:VICL) traded up 1.00% during trading on Wednesday, hitting $3.04. The company had a trading volume of 14,278 shares. Vical has a 52-week low of $2.80 and a 52-week high of $5.40. The stock’s 50-day moving average is $3.45 and its 200 day moving average is $3.98. The firm’s market capitalization is $27.99 million.

Vical (NASDAQ:VICL) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.14. Vical had a negative net margin of 30.81% and a negative return on equity of 14.18%. The company earned $4.10 million during the quarter, compared to the consensus estimate of $4.50 million. Equities research analysts predict that Vical will post ($0.86) earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in shares of Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the company’s stock worth $811,000 after buying an additional 476,499 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of Vical during the second quarter worth about $208,000. Eagle Global Advisors LLC bought a new position in shares of Vical during the second quarter worth about $178,000. Finally, BlackRock Fund Advisors boosted its position in shares of Vical by 32.5% in the second quarter. BlackRock Fund Advisors now owns 23,459 shares of the company’s stock worth $106,000 after buying an additional 5,750 shares during the period. Hedge funds and other institutional investors own 31.48% of the company’s stock.

Vical Company Profile

5 Day Chart for NASDAQ:VICL

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Inc. and related companies with's FREE daily email newsletter.